NasdaqGS:CYCN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$148.7m

Last Updated

2021/06/18 03:11 UTC

Data Sources

Company Financials

Executive Summary

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Cyclerion Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CYCN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: CYCN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-11.3%

CYCN

-2.5%

US Biotechs

-0.2%

US Market


1 Year Return

-18.0%

CYCN

23.1%

US Biotechs

39.4%

US Market

Return vs Industry: CYCN underperformed the US Biotechs industry which returned 23.1% over the past year.

Return vs Market: CYCN underperformed the US Market which returned 39.7% over the past year.


Shareholder returns

CYCNIndustryMarket
7 Day-11.3%-2.5%-0.2%
30 Day24.3%5.1%3.1%
90 Day-8.0%3.3%5.6%
1 Year-18.0%-18.0%24.9%23.1%41.7%39.4%
3 Yearn/a6.2%1.8%59.7%49.9%
5 Yearn/a54.6%42.5%122.6%97.6%

Long-Term Price Volatility Vs. Market

How volatile is Cyclerion Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cyclerion Therapeutics undervalued compared to its fair value and its price relative to the market?

2.59x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CYCN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CYCN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CYCN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CYCN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYCN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYCN is good value based on its PB Ratio (2.7x) compared to the US Biotechs industry average (3.4x).


Future Growth

How is Cyclerion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cyclerion Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Cyclerion Therapeutics performed over the past 5 years?

0.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYCN is currently unprofitable.

Growing Profit Margin: CYCN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYCN is unprofitable, but has reduced losses over the past 5 years at a rate of 0.7% per year.

Accelerating Growth: Unable to compare CYCN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYCN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: CYCN has a negative Return on Equity (-146.54%), as it is currently unprofitable.


Financial Health

How is Cyclerion Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CYCN's short term assets ($44.4M) exceed its short term liabilities ($13.5M).

Long Term Liabilities: CYCN's short term assets ($44.4M) exceed its long term liabilities ($38.1M).


Debt to Equity History and Analysis

Debt Level: CYCN's debt to equity ratio (7.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if CYCN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYCN has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: CYCN is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.


Dividend

What is Cyclerion Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CYCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYCN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYCN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYCN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.4yrs

Average management tenure


CEO

Peter Hecht (56 yo)

2.17yrs

Tenure

US$365,993

Compensation

Dr. Peter M. Hecht, Ph.D., served as the Chief Executive Officer of Ironwood Pharmaceuticals, Inc. since 1998 until April 1, 2019. Dr. Hecht is Chief Executive Officer and Director of Cyclerion Therapeutic...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD365.99K) is below average for companies of similar size in the US market ($USD1.05M).

Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CYCN's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: CYCN's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CYCN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.6%.


Top Shareholders

Company Information

Cyclerion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cyclerion Therapeutics, Inc.
  • Ticker: CYCN
  • Exchange: NasdaqGS
  • Founded: 2018
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$148.749m
  • Shares outstanding: 40.42m
  • Website: https://www.cyclerion.com

Number of Employees


Location

  • Cyclerion Therapeutics, Inc.
  • 301 Binney Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Biography

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/18 03:11
End of Day Share Price2021/06/17 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.